---
created: 2025-04-13
updated: 2025-04-13T10:51
id: e3@*`7WS7+
specialty: obgyn
specialty_id: 46
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - source/ak-step1-v11::
  - theme/b&b::14-msk::03-pathology::03-osteoporosis-drugs
  - source/ak-step1-v11::
  - theme/firstaid::10-hematology-oncology::05-pharm::25-selective-estrogen-receptor-modulators::raloxifene
  - source/ak-step1-v11::
  - theme/firstaid::15-repro::05-pharm::05-selective-estrogen-receptor-modulators
  - source/ak-step1-v11::
  - theme/firstaid::15-repro::05-pharm::05-selective-estrogen-receptor-modulators::raloxifene
  - source/ak-step1-v11::
  - theme/nbme::29
  - source/ak-step1-v11::
  - source/ome-banner
  - source/ak-step1-v11::
  - theme/physeo::09-pharm::12-reproductive::03-raloxifene,-clomiphene,-tamoxifen
  - source/ak-step1-v11::
  - theme/pixorize::03-pharm::11-oncology::raloxifene-and-tamoxifen
  - source/ak-step1-v11::
  - theme/sketchypharm::reproductive
  - source/ak-step1-v11::
  - theme/uworld::1000-9999::1000-1999::1795
  - source/ak-step1-v11::^other::^highyield::1-highyield
  - source/ak-step1-v11::^systems::reproductive::pharmacology
type: flashcard
---

# Question
Does raloxifene increase risk for endometrial cancer?   **No (estrogen antagonist at uterus)**

---

# Answer
However, Tamoxifen does